June 30, 2008

Wyeth K.K.
Takeda Pharmaceutical Company Limited

Launch of “ENBREL^® 25mg Syringe 0.5 mL for S.C. Injection”
New Formulation of ENBREL^®

Tokyo and Osaka, Japan --- June 30, 2008 – Wyeth K.K. (Wyeth) and Takeda Pharmaceutical Company Limited (Takeda) today announced the launch of “ENBREL^® 25mg Syringe 0.5mL for S.C. Injection,” a new formulation of ENBREL^® (generic name: etanercept) for the treatment of rheumatoid arthritis (RA), that is being co-promoted by the two companies.

ENBREL^® 25mg Syringe 0.5mL for S.C. Injection is a new formulation of the existing ENBREL^® 25mg for S.C. Injection, with the drug pre-filled into the syringe^{[ *1]}. Approval for its manufacture and sale was received from the Ministry of Health, Labour and Welfare on March 14 of this year, and the price for National Health Insurance was listed on June 20.

[ *1] Filled in a glass or plastic syringe for a single time use

The launch of ENBREL^® 25mg Syringe 0.5mL for S.C. Injection offers easier preparations for administration for patients who self-inject ENBREL^® as well as medical professionals, leading to a significant decrease in the burden for them.

Wyeth and Takeda believe that both companies have been contributing a lot to the treatment of RA in Japan through the marketing of the epoch-making biologic treatment ENBREL^®. Supported by the evidence of safety and efficacy profile demonstrated from post-marketing surveillance of more than 14,000 cases in Japan, Wyeth and Takeda are pleased to offer a more convenient treatment option for RA patients with the new formulation ENBREL^® 25mg Syringe 0.5mL for S.C. Injection.

Product Description

Product name	ENBREL® 25 mg Syringe 0.5 mL for S.C. Injection
Generic name	Etanercept
Indications	Rheumatoid arthritis (only for patients with inadequate response to existing treatments)
Use/Dose	Normally, for adults, 10-25 mg of etanercept (genetically modified) is injected once-daily, twice per week, subcutaneously.
Date of approval for sale	March 14, 2008
Date of NHI price listing	June 20, 2008
Date of launch	June 30, 2008

###

ABOUT RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic, chronic and potentially disabling disorder that affects about 700,000 people^{[ *2]} in Japan. The serious rheumatic disease causes the body's immune system to attack the lining of the joints, resulting in pain and swelling and may lead to fatigue, disability, deformity, organ damage, or premature death if not managed effectively. In RA, the immune system attacks the body’s own cells, mistaking them for cells that do not belong. This causes inflammation mainly in synovial membrane of the joints. Generally, in Japan the disease affects about four times as many women as men^{[ *3]}. RA can develop at all ages including childhood; in most cases it develops between the ages of 40 and 50^{[ *4]}.

[ *2][ *3] The Japan Medical Association

[ *4] Guidelines for management of rheumatoid arthritis 2004 update

ABOUT ENBREL

In Japan, ENBREL has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies. ENBREL acts by binding TNF-alpha, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions causing the inflammatory process of rheumatoid arthritis. The binding of ENBREL to TNF-alpha renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity. Additionally, ENBREL binds to LT-alpha, another cytokine involved in the inflammatory process of RA.

Globally physicians have become familiar with the benefits and proven long-term profile of ENBREL. To date, the product has been approved in more than 70 countries around the world, and has been used to treat more than 470,000 patients worldwide across various indications.

ABOUT WYETH

Wyeth K.K. is engaged in a full range of pharmaceutical business activities including developing, importing and marketing pharmaceutical products with the aim of becoming a leading company in the pharmaceutical industry in Japan. Our corporate vision is “Leading the way to a healthier world.” We strive to achieve this vision by bringing to the world pharmaceutical and health-care products that improve peoples’ lives and deliver outstanding value to our customers. Headquartered in Tokyo, Wyeth K.K. has approximately 1,000 employees. For more information, please visit

ABOUT TAKEDA

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: “lifestyle-related diseases,” “oncology and urological diseases (including gynecology),” “central nervous system diseases (including bone and joint disorders,” and “gastroenterological diseases.”

CONTACT

Wyeth K.K.	Takeda Pharmaceutical Company Limited
Corporate Affairs	Corporate Communications Department
+81-3-6420-6907	+81-3-3278-2037